Life Sciences

Serving life sciences companies for more than 25 years, Latham & Watkins represents leading and emerging companies in this broad and rapidly evolving industry.

Why Latham

Strategic Counsel

Life sciences companies worldwide rely on Latham’s unique combination of industry knowledge, legal acumen and strategic business expertise. Many of the firm’s lawyers hold advanced scientific degrees and have hands-on experience working in life sciences companies or within the government agencies that regulate the industry.

This deep understanding of the global life sciences industry allows Latham's lawyers to offer superior counsel to clients involved in transactions, investigations, litigation, intellectual property matters and regulatory challenges. They understand the economic, market, regulatory and political climates in which life sciences companies operate and integrate these factors when addressing clients’ legal and business needs.

Client-focused Representation

Latham represents public and private life sciences companies at all stages of development, from start-up and emerging growth to mature public companies, in the following industries:

  • Biofuels
  • Bioinformatics
  • Biotechnology
  • Cosmeceuticals 
  • Diagnostics
  • Drug delivery
  • eHealth
  • Genomics
  • Healthcare
  • Medical devices
  • Nanotechnology
  • Pharmaceuticals
  • Proteomics
  • Therapeutics

In addition, the firm’s lawyers play important roles in the industry, serving as primary outside counsel for the Advanced Medical Technology Association and as primary outside FDA counsel to the Medical Device Manufacturers Association. Latham also is a leader in key life sciences industry organizations including BIO, BayBio and BIOCOM.

Deep Industry Knowledge

Latham lawyers work closely with life sciences clients to address their legal needs and achieve their goals throughout the full life cycle of their companies. The firm also serves as company counsel in a range of areas, including:

Lawyers in this group assist clients in raising capital in:

The firm’s mergers and acquisitions work in the life sciences industry routinely includes:

Latham’s regulatory and enforcement work in the life sciences industry covers:

And its technology transactions have included:

  • Asset acquisitions
  • Commercial contracts and license agreements
  • Commercialization channel and sales agreements
  • Joint ventures
  • Outsourcing
  • R&D agreements
  • Strategic alliances
  • Supply and manufacturing agreements
  • University licensing

 Finally, Latham provides IP counseling and litigation services in areas such as:

Awards & Rankings

   
  • Six Partners Honored as 2018 Rising Stars - July 30, 2018
  • Intellectual Property Litigation Partner Named a Rising Star - May 16, 2018
  • Two Bay Area Partners Honored as Top Women Lawyers - May 15, 2018
  • Global Co-Chair Named Regulatory Trailblazer - May 06, 2018
  • Latham Honored as Capital Markets Practice Group of the Year - January 21, 2018

Latham has “a best-in-market corporate team with a sterling reputation for its counsel on M&A transactions, public and private securities offerings, and strategic partnerships.” They offer "a true cross-border life sciences focus", and have "high-powered transactional and IP litigation capabilities."
Chambers USA 2018

Events

FDLI Annual ConferenceWebcast: Recent Developments in Health Care Enforcement

Media Coverage

PTAB Nixes CardioNet Unit's Heart Monitor PatentLatham Wins One for Orphan DrugTop 40 Under 40: Jennifer Koh

News

Talented Patent Litigator Joins Latham & Watkins in Washington, D.C.Six Partners Honored as 2018 Rising StarsNew York Litigation Team Earns Complete Victory for Aratana Therapeutics in Securities Class Action

Thought Leadership

OIG Provides Regulatory Considerations for Gainsharing Agreements in Advisory Opinion 17-09Policy Developments, Enforcement, and Priority Initiatives for 2018Pharma and Biotech: Key Trends and Legal Risks